{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T16:33:29Z","timestamp":1767803609561,"version":"3.49.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Eat Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atypical anorexia nervosa is an eating disorder that involves significant restriction of food intake leading to clinically significant weight loss despite remaining at a normal or above normal weight for age or height. Part of rehabilitation involves increasing calorie intake for nutritional rehabilitation and weight gain to an appropriate percentage of ideal body weight, determined based on patient weight history. This report highlights the importance of considering how increased food intake in a previously malnourished patient can affect the metabolism of medications they are taking for the management of co-occurring psychiatric conditions, including the possibility of the emergence or re-emergence of tardive dyskinesia for a patient on an antipsychotic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>This case presents a 43-year-old female with a history of bipolar disorder type 1, controlled on lurasidone, admitted to an inpatient eating disorder unit for nutritional rehabilitation and weight restoration for atypical anorexia nervosa. Shortly after admission, despite no initial change in medication dosing, the patient began exhibiting symptoms of tardive dyskinesia. These symptoms were reduced once her lurasidone dose was decreased.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Nutritional rehabilitation likely has an impact on the metabolism of certain antipsychotic medications including lurasidone. More research is needed involving patients recovering from a restrictive eating disorder who are on antipsychotic medications and the frequency of increased side effects, including tardive dyskinesia, with refeeding.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40337-025-01466-w","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T11:34:48Z","timestamp":1764156888000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Food for thought: re-emergence of tardive dyskinesia amid nutritional rehabilitation of atypical anorexia nervosa; a case report"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7986-149X","authenticated-orcid":false,"given":"Nicole","family":"Gulino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ally","family":"Reardon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4894-5957","authenticated-orcid":false,"given":"Matthew J.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"1466_CR1","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s40337-022-00720-9","volume":"10","author":"M Vo","year":"2022","unstructured":"Vo M, Golden N. Medical complications and management of atypical anorexia nervosa. J Eat Disord. 2022;10:196. https:\/\/doi.org\/10.1186\/s40337-022-00720-9.","journal-title":"J Eat Disord"},{"key":"1466_CR2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders (DSM-5(R))","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5(R)). 5th ed. Washington, DC: American Psychiatric Association Publishing; 2013.","edition":"5"},{"issue":"7","key":"1466_CR3","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s11920-022-01340-5","volume":"24","author":"AF Muratore","year":"2022","unstructured":"Muratore AF, Attia E. Psychopharmacologic management of eating disorders. Curr Psychiatry Rep. 2022;24(7):345\u201351. https:\/\/doi.org\/10.1007\/s11920-022-01340-5.","journal-title":"Curr Psychiatry Rep"},{"issue":"3","key":"1466_CR4","doi-asserted-by":"publisher","first-page":"e0278189","DOI":"10.1371\/journal.pone.0278189","volume":"18","author":"S Thorey","year":"2023","unstructured":"Thorey S, Blanchet C, Guessoum SB, Moro MR, Ludot M, Carretier E. Efficacy and tolerance of second-generation antipsychotics in anorexia nervosa: A systematic scoping review. PLoS ONE. 2023;18(3):e0278189. https:\/\/doi.org\/10.1371\/journal.pone.0278189.","journal-title":"PLoS ONE"},{"issue":"1","key":"1466_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.5455\/pbs.20241104052122","volume":"15","author":"R Ekinci","year":"2025","unstructured":"Ekinci R, Uygun E. Mechanism of action and uses of lurasidone, a new generation of antipsychotics: A review. PBS. 2025;15(1):25. https:\/\/doi.org\/10.5455\/pbs.20241104052122.","journal-title":"PBS"},{"issue":"2","key":"1466_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/j.1600-0447.1986.tb10588.x","volume":"73","author":"JT Condon","year":"1986","unstructured":"Condon JT. Long-term neuroleptic therapy in chronic anorexia nervosa complicated by tardive dyskinesia: A case report. Acta Psychiatr Scand. 1986;73(2):203\u20136. https:\/\/doi.org\/10.1111\/j.1600-0447.1986.tb10588.x.","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"1466_CR7","doi-asserted-by":"publisher","first-page":"e00615","DOI":"10.1002\/prp2.615","volume":"8","author":"P Sandvik","year":"2020","unstructured":"Sandvik P, Lydersen S, Hegstad S, Spigset O. Association between low body weight and cytochrome P-450 enzyme activity in patients with anorexia nervosa. Pharmacol Res Perspec. 2020;8(3):e00615. https:\/\/doi.org\/10.1002\/prp2.615.","journal-title":"Pharmacol Res Perspec"},{"issue":"5","key":"1466_CR8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40262-016-0465-5","volume":"56","author":"WM Greenberg","year":"2017","unstructured":"Greenberg WM, Citrome L. Pharmacokinetics and pharmacodynamics of Lurasidone hydrochloride, a second-generation antipsychotic: A systematic review of the published literature. Clin Pharmacokinet. 2017;56(5):493\u2013503. https:\/\/doi.org\/10.1007\/s40262-016-0465-5.","journal-title":"Clin Pharmacokinet"},{"key":"1466_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-025-01457-4","author":"WJ Hayes","year":"2025","unstructured":"Hayes WJ, Stegenga M, Kappes JA, Berendse J. Pharmacotherapy considerations in underweight patients with anorexia nervosa: A narrative review. Clin Drug Investig. 2025. https:\/\/doi.org\/10.1007\/s40261-025-01457-4. (Published online June 24, 2025)","journal-title":"Clin Drug Investig"},{"issue":"5","key":"1466_CR10","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/0006-2952(67)90060-3","volume":"16","author":"R Kato","year":"1967","unstructured":"Kato R. Effects of starvation and refeeding on the oxidation of drugs by liver microsomes. Biochem Pharmacol. 1967;16(5):871\u201381. https:\/\/doi.org\/10.1016\/0006-2952(67)90060-3.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"1466_CR11","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/0016-5085(85)90321-X","volume":"89","author":"EJ Pantuck","year":"1985","unstructured":"Pantuck EJ, Pantuck CB, Weissman C, Gil KM, Askanazi J. Stimulation of oxidative drug metabolism by parenteral refeeding of nutritionally depleted patients. Gastroenterology. 1985;89(2):241\u20135. https:\/\/doi.org\/10.1016\/0016-5085(85)90321-X.","journal-title":"Gastroenterology"},{"issue":"2","key":"1466_CR12","first-page":"162","volume":"17","author":"EM Cornett","year":"2017","unstructured":"Cornett EM, Novitch M, Kaye AD, Kata V, Kaye AM. Medication-Induced tardive dyskinesia: A review and update. Ochsner J. 2017;17(2):162\u201374.","journal-title":"Ochsner J"},{"key":"1466_CR13","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp-rj.2023.180306","author":"T DePietro","year":"2023","unstructured":"DePietro T, Lumateperone. A truly innovative antipsychotic medication? Am J Pysch Res J. 2023. https:\/\/doi.org\/10.1176\/appi.ajp-rj.2023.180306.","journal-title":"Am J Pysch Res J"},{"issue":"6","key":"1466_CR14","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s00280-021-04352-9","volume":"88","author":"Y Chen","year":"2021","unstructured":"Chen Y, Tang Y, Nie JZ, Zhang Y, Nie D. Megestrol acetate is a specific inducer of CYP3A4 mediated by human pregnane X receptor. Cancer Chemother Pharmacol. 2021;88(6):985\u201396. https:\/\/doi.org\/10.1007\/s00280-021-04352-9. Epub 2021 Sep 15.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"1466_CR15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/hup.2338","volume":"28","author":"S Preskorn","year":"2013","unstructured":"Preskorn S, Ereshefsky L, Chiu YY, Poola N, Loebel A. Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies. Hum Psychopharmacol. 2013;28(5):495\u2013505. https:\/\/doi.org\/10.1002\/hup.2338.","journal-title":"Hum Psychopharmacol"},{"key":"1466_CR16","unstructured":"FDA. Latuda (lurasidone hydrochloride) tablets. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/200603lbls10s11.pdf. Accessed 1 Nov 2025."},{"issue":"3","key":"1466_CR17","first-page":"22br03378","volume":"25","author":"A Naguy","year":"2023","unstructured":"Naguy A, Pridmore S, Alamiri B. The ofttimes overlooked food-drug interactions in psychopharmacotherapy. Prim Care Companion CNS Disord. 2023;25(3):22br03378.","journal-title":"Prim Care Companion CNS Disord"}],"container-title":["Journal of Eating Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40337-025-01466-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40337-025-01466-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40337-025-01466-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T12:54:34Z","timestamp":1767790474000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40337-025-01466-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1466"],"URL":"https:\/\/doi.org\/10.1186\/s40337-025-01466-w","relation":{},"ISSN":["2050-2974"],"issn-type":[{"value":"2050-2974","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"31 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This case report of a single patient is not considered human subject research and thus did not require ethics approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient provided verbal and written consent for this case report to be written and published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}